Phase 1 study of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma
ID Number 15-1275Principal Investigator(s)
Hearn Jay Cho
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance to see what side effects it may have and how well it works for the treatment of symptomatic multiple myeloma diagnosed and treated with induction therapy in the past year.
You may qualify to take part in this research study because you have symptomatic multiple myeloma that has been diagnosed and treated in the past year and you are eligible for autologous stem cell transplant.
Recruiting Patients: Yes